A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study

摘要: Background. Multiple myeloma is considered to be a drug responsive disease; however, there no cure for this disease and virtually all patients will develop resistance. One form of resistance that has been documented the multidrug phenotype or MDR. Methods. A randomized trial combination vincristine, doxorubicin, dexamethasone (VAD) VAD plus oral verapamil (VAD/v) in refractory multiple was performed by South-western Oncology Group. Verapamil used as chemosensitizing agent attempt overcome prevent MDR improve therapeutic outcome. Results. Response rates between two treatment arms were similar with an overall response rate 41% alone arm 36% VAD/v arm. Overall survival also median 10 months 13 The toxicity profile both treatments, myelosuppression being dose-limiting toxicity. No significant correlation observed expression P-glycoprotein, serum levels, therapy. Conclusions. beneficial effect from addition chemotherapy regimen drug-resistant patients. More effective less toxic chemosensitizers are needed study role reversing clinic. Cancer 1995;75:815-20.